Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Article
    Yang IP, Tsai HL, Huang CW, Huang MY, Hou MF, Juo SH, Wang JY.
    PLoS One. 2013;8(6):e66842.
    BACKGROUND: The recurrence of colorectal cancer (CRC) is frequent within the first year of curative resection surgery and may be unavoidable. microRNAs have been suggested to play roles in carcinogenesis and cancer recurrence. We recently identified microRNA-29c (miRNA-29c) as a predictor of early recurrence in CRC. In the present study, we further investigated the functions and serum level of miRNA-29c in relation to early recurrence of CRC.
    METHODS: First we further confirmed overexpression of miRNA-29c in non-early relapse subjects. Gain-of-function in vitro studies were used to evaluate the effect of miRNA-29c on cell proliferation, migration, invasion, and cell cycle progression. The colon cancer cell line Caco2 and a stable clone overexpressing miRNA-29c were xenografted to evaluate the in vivo effect of miRNA-29c in null mice. Finally, circulating miRNA-29c was investigated as a potential biomarker for identifying early relapse.
    RESULTS: miRNA-29c expression significantly decreased during early relapse compared to non-early relapse in UICC stage II and III CRC patients (P = 0.021). In vitro studies showed that overexpression of miRNA-29c inhibited cell proliferation and migration. The cell cycle studies also revealed that miRNA-29c caused an accumulation of the G1 and G2 population. In vivo, miRNA-29c suppressed tumor growth in null mice. The serum miRNA-29c increased significantly in early relapsed patients compared to non-early elapsed patients (P = 0.012).
    CONCLUSIONS: miRNA-29c shows anti-tumorigenesis activity, and preoperative circulating miRNA-29c levels can be used to predict postoperative early relapse of CRC.
    Digital Access Access Options
  • Book
    Jacqueline M. Loversidge, Joyce Zurmehly.
    Summary: "What happens in health policy at local, state, and federal levels directly affects patients, nurses, and nursing practice. Some healthcare professionals, though, are intimidated by the complex and often nonlinear policy process or simply don't know how to take the first step toward implementing policy change. In the second edition of Evidence-Informed Health Policy, authors Jacqueline M. Loversidge and Joyce Zurmehly demystify health policymaking and equip nurses and other healthcare professionals with the knowledge, tools, and confidence to navigate the first of many steps into health policy. This book translates the EBP language of clinical decision-making into an evidence-informed health policy (EIHP) model-a foundation for integrating evidence into health policymaking and leveraging dialogue with stakeholders. Readers will develop a stronger understanding of policymaking and its role within government, learn strategies for influencing policymakers, and help shape future healthcare policy that makes the best use of evidence. This new edition includes: Fresh perspectives on the use of evidence to inform smart health policy, learned knowledge of the COVID-19 pandemic and global crisis to more effectively strategize for sound policy informed by the best science, a new visual graphic representation of the EIHP Model with added descriptions of the EIHP process, and additional breadth and depth on policymaking theories and models"-- Provided by publisher.
    Digital Access R2Library [2023]